Analyzing ArriVent BioPharma (NASDAQ:AVBP) & Foghorn Therapeutics (NASDAQ:FHTX)

ArriVent BioPharma (NASDAQ:AVBP) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Risk and Volatility

ArriVent BioPharma has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500.

Institutional & Insider Ownership

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 18.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ArriVent BioPharma and Foghorn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-62.49%	-58.11%
Foghorn Therapeutics	-240.33%	N/A	-33.46%

Earnings & Valuation

This table compares ArriVent BioPharma and Foghorn Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31 million	($4.41)	-7.02
Foghorn Therapeutics	$30.91 million	10.01	-$74.28 million	($1.17)	-4.50

Foghorn Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ArriVent BioPharma and Foghorn Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1	1	8	2	2.92
Foghorn Therapeutics	1	0	8	1	2.90

ArriVent BioPharma presently has a consensus target price of $41.67, indicating a potential upside of 34.50%. Foghorn Therapeutics has a consensus target price of $11.13, indicating a potential upside of 111.10%. Given Foghorn Therapeutics’ higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than ArriVent BioPharma.

Summary

Foghorn Therapeutics beats ArriVent BioPharma on 9 of the 13 factors compared between the two stocks.

About ArriVent BioPharma

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

About Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.